Testing for 2,4-dinitrophenol in human hair by LC-MS/MS and interpretation issues.


Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
05 Jan 2024
Historique:
received: 07 09 2023
revised: 07 10 2023
accepted: 11 10 2023
medline: 3 11 2023
pubmed: 16 10 2023
entrez: 16 10 2023
Statut: ppublish

Résumé

2,4-dinitrophenol, initially developed for industrial purposes, is used in the synthesis of dyes and various drugs, including herbicides, fungicides and insecticides. Incidentally, it was discovered that 2,4-dinitrophenol increases human basal metabolic rate. As a consequence, people who want to loose weight can abuse 2,4-dinitrophenol. It is a compound of choice for bodybuilders who abuse it in combination with anabolic steroids and clenbuterol. Numerous deaths have been attributed to 2,4-dinitrophenol. Up to now, 2,4-dinitrophenol was never reported in hair. The authors present an original method to test for 2,4-dinitrophenol in hair after methanolic extraction using LC-MS/MS. The limit of detection of the procedure is 0.01 ng/mg and the method was fully validated in the range 0.1-50 ng/mg. 2,4-dinitrophenol tested positive in the brown hair of a subject deceased from acute poisoning at 5.15, 13.06 and 25.48 ng/mg in the 3 × 3 cm segments. As excessive sweating is associated to 2,4-dinitrophenol abuse, major contribution of this matrix must be taken into consideration when interpreting the data. In this case, there was a regular increase of 2,4-dinitrophenol concentration from root to tip. This specific pattern can be the consequence of sweat contamination, i.e., the older hair being for a longer time in contact with sweat.

Identifiants

pubmed: 37844362
pii: S0731-7085(23)00564-2
doi: 10.1016/j.jpba.2023.115795
pii:
doi:

Substances chimiques

2,4-Dinitrophenol Q13SKS21MN
Clenbuterol XTZ6AXU7KN

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115795

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Pascal Kintz (P)

X-Pertise Consulting, 42 rue principale, 67206 Mittelhausbergen, France; Institut de Médecine légale, 11 rue Humann, 67000 Strasbourg, France. Electronic address: pascal.kintz@wanadoo.fr.

Alice Ameline (A)

Institut de Médecine légale, 11 rue Humann, 67000 Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH